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Summary 
Spinocerebellar ataxia type I (SCA1) is an autosomal 
dominant inherited disorder characterized by degener- 
ation of cerebellar Purkinje cells, spinocerebellar tracts, 
and selective brainstem neurons owing to the expan- 
sion of an unstable CAG trinucleoUde repeat. To gain 
insight into the pathogenesis of the SCA1 mutation 
and the intergenerational stability of trinucleotide re- 
peats in mice, we have generated transgenic mice ex- 
pressing the human SCA1 gene with either a normal 
or an expanded CAG tract. Both transgenes were sta- 
ble in parent to offspring transmissions. While all six 
transgenic lines expressing the unexpanded human 
SCA1 allele had normal Purkinje cells, transgenic ani- 
mals from five of six lines with the expanded SCA1 
allele developed ataxia and Purkinje cell degeneration. 
These data indicate that expanded CAG repeats ex- 
pressed in Purkinje cells are sufficient to produce de- 
generation and ataxia and demonstrate that a mouse 
model can be established for neurodegeneration caused 
by CAG repeat expansions. 
Introduction 
Spinocerebellar ataxia type 1 (SCA1) is an; autosomal .. 
dominant inherited neurologic disorder characterized 
pathologically by loss of Purkinje cells in the cerebellar 
cortex and neurodegeneration within the brainstem and 
spinocerebellar tracts (Zoghbi and Orr, 1995). Clinical fea- 
tures of SCA1 include limb and gait ataxia, dysarthria, 
dysmetria, nystagmus, and variable degrees of muscle 
wasting and neu ropathy. Although several cases of SCA1 
in juveniles have been reported (Haines et al., 1984; 
Zoghbi et al., 1988), SCA1 is typically considered an adult- 
onset disorder, in which symptoms appear within the third 
or fourth decade of life and progressively worsen over a 
period of 10 to 30 years, ultimately resulting in death owing 
to brainstem dysfunction. 
The SCA1 gene has been localized to 6p22-p23 based 
on detailed genetic and physical mapping studies (Zoghbi 
et al., 1991 ; Ranum et al., 1991; Kwiatkowski et al., 1993; 
Banff et al., 1993). Using a positional cloning strategy, 
the SCA1 gene was isolated, and the mutational basis of 
disease was determined to be the expansion of an unsta- 
ble CAG trinucleotide repeat located within the coding re- 
gion of the identified gene (Orr et al., 1993; Banff et al., 
1994). Among unaffected chromosomes, the SCA1 CAG 
repeat is highly polymorphic, with a heterozygosity rate 
of 84% (Ranum et al., 1994). Sequence analysis of the 
repeat from unaffected and affected chromosomes re- 
vealed that 98% of the unexpanded alleles had an inter- 
rupted repeat configuration with at least one CAT triplet 
interspersed between two CAG repeat tracts (Chung et 
al., 1993). The overall size of the trinucleotide repeat on 
unaffected alleles ranges from 6 to 40 U (Orr et al., 1993; 
Chung et al., 1993; Matilla et al., 1993; Ranum et al., 1994; 
Jodice et al., 1994). The remaining 2% of normal alleles 
that lack the CAT interruption contain fewer than 21 re- 
peats. Expanded SCA1 alleles, on the other hand, have 
perfect CAG repeat tracts without a CAT interruption and 
range in size from 40 to 83 repeat units. 
Interrupted normal alleles and uninterrupted expanded 
alleles display dramatically different stability characteris- 
tics. A study of more than 600 germline transmissions of 
normal alleles containing at least one CAT interruption 
failed to detect a single instance of repeat instability (Jod- 
ice et al., 1994). Conversely, uninterrupted expanded al- 
leles are highly unstable and change in size in approxi- 
mately 70% of transmissions (Chung et al., 1993; Ranum 
et al., 1994). Paternal transmissions of expanded alleles 
often result in further expansions of the CAG repeat and 
subsequently earlier ages of onset of disease (Chung et 
al., 1993). In contrast, maternal transmissions of ex- 
panded alleles tend to yield contractions in repeat number. 
Polymerase chain reaction (PCR) analyses performed on 
either single sperm or small quantities of genomic DNA 
have suggested that loss of the CAT interruption in the 
CAG tract is an early step in the process of expansion and 
the development of repeat instability (Chong et al., 1995). 
The wild-!ype SC~I gene encodes ataxin-1, a protein 
that consists of 792 to 826amino acids depending on the 
number of CAG trinucleotides (Servadio et al., 1995). The 
SCA 1 gene is highly homologous to. murine Sca I (S. Banff 
and H. Y. Z., unpublished data). Interestingly Scal con- 
tains only two CAGs at the site of the CAG tracts in SCA1. 
Data base searches have failed to reveal any significant 
homologies with previously characterized genes or pro- 
teins. Ataxin-1 is expressed in a variety of both neuronal 
and nonneuronal cell types. Furthermore, immunoblot 
studies have shown that both the unaffected and affected 
expanded alleles of SCA 1 are translated and produce pro- 
tein in both lymphoblastoid cell lines and cerebeilar tissue 
(Servadio et al., 1995). Immunohistochemical studies have 
revealed that ataxin-1 is cytoplasmic in nonneuronal cell 
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types and nuclear in neuronal cells in the brain with one 
notable exception, the Purkinje cells of the cerebellum 
(Servadio et al., 1995). In Purkinje cells, the cerebellar 
site of SCA1 pathology, ataxin-1 has both nuclear and 
cytoplasmic localization. 
SCA1 is a member of a family of neurodegenerative 
disorders caused by CAG repeat expansions. This family 
currently consists of spinal and bulbar muscular atrophy 
(SBMA) (La Spada et al., 1991 ), Huntington's disease (HD) 
(Huntington's Disease Collaborative Research Group 
[HDCRG], 1993), SCA1 (Orr et al., 1993), dentatorubral- 
pallidoluysian atrophy (Koide et al., 1994; Nagafuchi et 
al., 1994) and the allelic Haw-River syndrome (Burke et 
al., 1994), and, most recently, Machado-Joseph disease 
and the allelic type 3 spinocerebellar ataxia (Kawaguchi 
et al., 1994). The diseases in this group are neurodegener- 
ative in nature, are inherited in an autosomal dominant 
manner (except X-linked recessive SBMA), and often dis- 
play anticipation, worsening, and earlier onset in succes- 
sive generations. Interestingly, the coding regions of the 
genes associated with each disorder fail to share any ho- 
mologies to the other members of this group except in 
the highly polymorphic CAG tract, which is predicted to 
encode a stretch of glutamines. In each of the genes, the 
CAG tract on unaffected chromosomes is highly polymor- 
phic and on disease chromosomes is unstable, particularly 
when paternally transmitted. In addition, in each disorder 
the length of the CAG reiteration on affected chromo- 
somes correlates inversely with the age of onset and dis- 
ease severity, such that large repeats are found in juvenile 
onset cases. The striking similarities in clinical, genetic, 
and molecular features of these disorders suggest that, 
as a group, they share a common mechanism of pathogen- 
esis. Thus, insights obtained into any given disorder are 
likely to have important implications for the other members 
of this family. 
The molecular mechanism by which the expansion of 
the CAG tract leads to the loss of specific neurons remains 
unclear. We and others have proposed that the develop- 
ment of disease results from a gain of function in the mu- 
tant protein encoded by the expanded CAG allele. Several 
observations support this hypothesis. First, deletions of 
the androgen receptor (AR) and HD genes fail to result in 
SBMA or HD, respectively (Quigley et al., 1992; Gandel- 
man et al., 1992; HDCRG, 1993). A corollary to this point 
is that expansion of the CAG tract has a limited effect 
on normal gene function. Illustrative of this point is the 
observation that SBMA patients display minimal signs of 
testicular feminization, a hallm ark for loss of AR gene func- 
tion. Furthermore, individuals homozygous for the HD mu- 
tation have a disease that is no more severe than individu- 
als having only one mutant HD allele (Wexler et al., 1987), 
suggesting that HD is caused by a true dominant mutation. 
Finally, that both SBMA and HD disease phenotypes do 
not include symptoms associated with the loss of gene 
function, which are seen in patients with gene deletions, 
also argues against a classical dominant negative mecha- 
nism of pathogenesis, in which the mutant allele disrupts 
the function of the wild-type allele. 
To gain insight into the pathogenesis of SCA1 and to 
examine intergenerational stability of trinucleotide repeats 
in mice, we have generated transgenic animals harboring 
the human SCA 1 gene with either a normal or an expanded 
CAG tract, containing 30 or 82 repeats, respectively. Ex- 
pression of the transgenes was directed to cerebellar Pur- 
kinje cells, a primary site of SCA1 pathology, using the 
regulatory region of the Purkinje cell-specific gene Pcp2 
(Vandaele et al., 1991). 
Results 
SCA1 Transgenes 
In an effort to test the gain-of-function hypothesis, the pro- 
moter elements of the murine Pcp2 (L7) gene (Vandaele 
et al., 1991; Oberdick et al., 1990) were used to direct the 
expression of the human SCAl-coding region contain- 
ing either a normal interrupted allele with 30 repeats, 
(CAG)12CATCAGCAT(CAG)ls, or an expanded uninter- 
rupted allele containing 82 repeats. The resulting con- 
structs were designated PS-30 and PS-82, respectively. 
We (Vandaele et al., 1991; Feddersen et al., 1992, 1995) 
and others (Oberdick et al., 1990) have previously shown 
that the 5' regulatory sequences of the Pcp2 gene are 
capable of directing transgene expression specifically to 
Purkinje cells, the primary site of SCA1 cerebellar pathol- 
ogy. The simian virus 40 (SV40) polyadenylation signal 
was also included in these constructs to allow for proper 
processing of the transgene mRNA (Figure 1). 
To assess the translational capabilities of the SCA1 
cDNAs containing either 30 or 82 CAG repeats, the SCA1- 
coding regions from the PS-30 and PS-82 constructs were 
subcloned into pcDL-SR~296 (Takebe et al., 1988) and 
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Figure 1. Configuration of the Pcp2/SCA1 cDNA Transgenes 
The thin line depicts the 5' upstream regulatory region from Pcp2. 
Closed boxes indicate the first two noncoding exons from Pcp2 sepa- 
rated by the endogenous Pcp2 intron. The human SCA1 cDNA is de- 
picted by the stippled box. The open box depicts the poly(A) addition 
site from SV40. The (CAG). configurations are (CAG)12CATCAGCAT 
(CAG),5, designated (CAG)3o, for the unexpanded allele and (CAG)~ 
for the expanded allele. PCR primer sets A and B and Repl and Rep2 
are indicated within detailed view of the SCA/-coding region. Recogni- 
tion sites for the restriction enzyme Sill are indicated by an S. 
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Figure 2. Immunoblot Analysis of Ataxin-1 Expression in Transfected 
COS7 Cells 
COS7 cells transfected with SCA1 cDNAs containing either the 30 
or 82 CAG repeats express ataxin-1 of the expected size based on 
comparison with extracts from patients harboring similar numbers of 
repeats. Protein lysates (5 p.g) prepared from COS7 cells transfected 
with vector alone (pcDL-SRa296) or with vector containing a SCA1 
cDNA with either 30 or 82 CAG repeats (pcDL-SRa296-SCA1-30 and 
pcDL-SRa296-SCA1-82, respectively) were loaded. For comparison, 
we used 200 I~g of lymphoblastoid cell extracts from a normal individual 
(NL) with 29 and 30 CAG repeats and a SCAl-affected individual with 
26 and 83 CAG repeats. 
transfected into COS7 cells. Figure 2 shows that COS7 
cells transfected with either the pCDL-SRa296-SCA1-30 
or pCDL-SRa296-SCA1-82 construct expressed detect- 
able levels of ataxin-1 by Western blot analysis. Moreover, 
the size of the detected protein was consistent with the 
number of CAG repeats present within the SCA1 expres- 
sion construct. These results demonstrate that both the 
30 and 82 CAG repeat-containing SCA1 cDNAs encode a 
message capable of producing ataxin-1 of the appropriate 
size. 
The PS-30 and PS-82 transgenes were microinjected 
into single-cell FVB/N embryos as previously described 
(Hogan et ai., 1986; Taketo et al., 1991). Founder animals 
were identified using a transgene-specific PCR assay and 
backcrossed to the parental FVB/N strain to establish inde- 
pendent lines. 
A total of 12 founder animals (six for each transgenic 
construct) were identified. Transgene incorporation was  
determined by Southern blot analysis. One of the six 
founder animals containing the PS-30 transgene had two 
sites of transgene integration, allowing the establishment 
of seven independent lines containing this construct. Each 
of the six PS-82 founders had a single transgene integra- 
tion site, resulting in the establishment of six independent 
lines. Transgene copy number in each line was deter- 
mined by densitometric comparison of Southern blot 
hybridization intensities of N1 tail DNAs with known stan- 
dards. The transgenic lines obtained (see Table 1) con- 
tained between three and 200 copies of the transgene. 
Intergenerational Stability of the CAG Repeat 
within Transgenes 
To investigate the stability of the CAG trinucleotide se- 
quences Within the SCA1 transgenes, tail DNA was pre- 
pared and subjected to PCR using primers immediately 
flanking the CAG repeat (Repl and Rep2 in Figure 1), 
PCR products were obtained from 129 progeny of the six 
founder animals containing the PS-30 construct (A01, n = 
7; A02, n = 21; A03, n = 16; A04, n = 17; A05, n = 15; 
Table 1. Pcp2/SCA1 Transgenic Mouse Lines 
Transgene Analysis of Analysis of Analysis of Onset of 
Transgenic Line Copy Number mRNA (weeks) Protein (weeks) Pathology (weeks) Ataxia (weeks) 
PS-30 
A01 200 - (6,8) - (7) NO - (33) a 
A02 100 + (7,8,9) + (7,12,24) - (20,26,48) - (52) 
A03 5 + (4,7,22) + (6,14) ND - (43) a 
A04 5 + (5,9) + (12) ND - (43) a 
A05 20 + (6,9) + (8,16) N D - (42) a 
A06.1 50 + (6,7,12) + (10,13,18) - (36,48) - (52) 
A06.2 200 + (12,16) + (10,14) - (20) - (40) 
PS-82 
B01 30 + (8,14) - (4,12) - (7) - (36) 
+ (26) b + (24) b 
B02 10 + (5,11,18) - (4,11) + (36) - (36) 
+ (26) b + (2O) b 
B03 50 - (8,9) - (12,19) - (26) - (20) 
B04 3-5 + (10,14) - (11,12,17) + (17,29) + (16) 
B05 30 + (10) - (5,11,16) + (16) + (12) 
B06 10 + (9,14) - (4,9) + (26) + (26) 
Transgenic animals were analyzed for mRNA by Northern blot analysis, protein by Western blot analysis, and pathology by hematoxylin- and 
eosin-stained cerebellar sections at the ages indicated in parentheses. Age of onset of ataxia or absence of a phenotype in the oldest animal is 
also indicated. Plus indicates positive; minus indicates negative. ND, not done. 
a Time at which line was discarded. 
b These animals were homozygotes; all others were transgene heterozygotes. 
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Figure 3. Intergenerational Stability of the SCA1 (CAG)n Repeat in 
Transgenic Mice 
Sequencing gel analysis of PCR products amplified from tail DNA of 
mice containing either the PS-30 (A) or PS-82 transgene (B). The sizes 
of the 30- and 82-repeat units are indicated. Each lane contains amplifi- 
cation products from DNA of a different animal. The primary PCR 
product obtained from each animal showed no change in repeat length. 
There were, however, minor line-specific PCR products observed in 
several of the PS-82 transgenic lines (B). These products were also 
stably transmitted. 
A06, n -- 61) and from 125 progeny of six founder animals 
containing the PS-82 construct (B01, n = 29; B02, n = 
37; B03, n -- 20; B04, n = 19; B05, n -- 7; B06, n -- 11). 
The animals examined included groups of progeny that 
had either paternally or maternally inherited the trans- 
gene. In all 254 animals examined, the primary PCR prod- 
uct showed no change in repeat size as compared with 
the microinjected transgene. Representative results are 
shown in Figure 3. Four of the six lines containing the 
PS-82 transgene did have line-specific amplification prod- 
ucts, albeit at reduced quantities relative to the 82-repeat 
product. In each case, the additional PCR product was 
amplified from founder DNA and was smaller than the 
full-length 82-repeat ract present in the microinjected con- 
struct. Importantly, these products were observed in the 
amplification products of all the progeny of the line in- 
volved, indicating the meiotic stability of the CAG trinucleo- 
tide tract over a variety of size ranges. These results indi- 
cate that in some copies of the transgene within a tandem 
array there was rearrangement of the CAG repeat upon 
integration into the murine genome. 
Transgene Expression 
Expression of the transgene in each of the lines was as- 
sessed by reverse transcriptase-PCR reaction (data not 
shown) and Northern blot analyses (Figure 4). Of the 13 
PS transgenic lines, five lines either failed to express the 
transgene (A01 and B03) or expressed the transgene at 
significantly lower levels than murine Sca I (A03, A04, and 
A05; data not shown). Lines A02, A06.1, and A06.2 had 
comparable levels of transgene expression, approxi- 
mately 50- to 100-fold greater than endogenous murine 
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Figure 4. Northern Blot Analysis of Cerebellar RNA from PS-30 and 
PS-82 Transgenic Mice 
Total RNA was prepared from the cerebellum of a single animal from 
each of the transgenic lines at the age in weeks (wk) indicated. RNA 
(15 ilg) from each animal was fractionated on a glyoxyl-sodium phos- 
phate-agarose (1%) gel and blotted to a nylon membrane. The mem- 
brane was sequentially hybridized with human SCA1 and glyceral- 
dehyde 3-phosphate dehydrogenase (GAPDH) cDNA probes. The 
positions of the endogenous Scal, transgene, and GAPDH transcripts 
are indicated. All lines shown, except B03, expressed the transgene 
at levels 10- to 100-fold greater than Sca 1. The slightly reduced electro- 
phoretic mobility of the transgene message in the expressing B lines 
is due to the increased length of the CAG tract in the PS-82 transgenic 
animals• 
Scal (Figure 4). The PS-82-expressing lines had levels of 
transgene RNA expression approximately 10-fold (B04), 
50-fold (B01, B02, and B06), and 100-fold (B05) greater 
than endogenous levels of Scal RNA (Figure 4). 
Immunoblot analysis of protein extracts from cerebellar 
and total brain tissue using anti-ataxin-1 antisera (Ser- 
vadio et al., 1995) revealed expression of human ataxin-1 
in transgenic lines harboring the PS-30 gene (Figure 5). 
Surprisingly, human ataxin-1 protein could not be detected 
in transgenic lines with the PS-82 transgene (Figure 5), 
despite abundant levels of transgene RNA (see Discus- 
sion). The immunoblot analyses were done using tissues 
obtained at a variety of postnatal timepoints (Table 1). 
Neurological Phenotype 
The ataxic neurological phenotype provides evidence for 
disrupted Purkinje cell function. PS-30 transgenic animals 
expressing the normal human SCA 1 allele, currently more 
than 1 year of age, display a normal neurological pheno- 
type, indicating intact Purkinje cell function. The apparent 
wild-type phenotype of these animals suggests that over- 
expression of normal human ataxin-1, despite the in- 
creased length of the polyglutamine tract relative to endog- 
enous murine ataxin-1 (two glutamines; S. Banff and 
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Figure 5. Expression Analysis of Normal and Expanded Human 
Ataxin-1 Protein in Transgenic Mice 
Protein extracts from brain or cerebella of normal and transgenic mice, 
as well as from lymphoblasts obtained from normal (NL) and SCA1- 
affected individuals, were analyzed by immunoblotting. Tissue sources 
are indicated above each lane. The number of CAG repeats within 
the human SCA1 and the murine Scal gene for both alleles are shown 
below each lane. The number of CAG repeats within the Pcp2/SCA1 
transgene cDNA is indicated within the brackets. 
(A) Murine ataxin-1 is detected in brain extracts of a nontransgenic 
mouse and is clearly smaller than wild-type human ataxin-l. In 
transgenic animals harboring the PS-30 transgene, a denser band is 
seen, which extends into the size range of wild-type human ataxin-1, 
indicating that human ataxin-1 is translated from the transgene. Only 
wild-type murine ataxin-1 is detected in transgenic animals harboring 
the PS-82 transgene. Analysis of lymphoblast protein extracts from 
H. Y. Z., unpublished data), is not detrimental to murine 
Purkinje cell differentiation, maintenance, or function. 
Conversely, transgenic animals from all five lines ex- 
pressing the human PS-82 transgene developed ataxia 
and displayed an abnormal neurological phenotype when 
compared with nontransgenic littermates. In the first 8-10 
weeks of life, the unusual phenotype was subtle but suffi- 
ciently distinctive to allow identification of transgenic ani- 
mals. Phenotypic abnormalities included slightly reduced 
cage activity, a gentle swaying of the head while walking, 
and early signs of general incoordination. These abnor- 
malities gradually became more profound over the next 
6-20 weeks, until the animals were clearly ataxic when 
walking (Figure 6) and routinely fell when attempting to 
stand on their hind legs. 
The onset of the neurological abnormalities and discern- 
ible ataxia varied in the transgenic lines (Table 1). Hetero- 
zygous animals in the highest expressing line, B05, had 
the earliest onset of ataxia (12 weeks). B04 heterozygous 
animals developed ataxia at approximately 16 weeks. Al- 
though heterozygous B01 and B02 animals express the 
transgene at levels approximately 50-fold higher than en- 
dogenous Sca I (see Figure 4) and are currently more than 
36 weeks old, they do not display signs of ataxia. In con- 
trast, homozygous animals in these lines become ataxic 
at 24 and 20 weeks, respectively. Another transgenic line, 
B06, also expresses transgene mRNA at a level substan- 
tially above that seen in transgenic B04 animals (see Fig- 
ure 4), yet B06 animals display only subtle signs of ataxia 
at 26 weeks of age. These results suggest that SCA1 
transgene mRNA levels and the onset of ataxia are not 
strictly correlated. 
Pathology 
Pathologic examination of several of the PS-30 transgenic 
lines (Table 1) revealed no gross or microscopic abnormal- 
ities of the cerebellum. Similarly, the PS-82 transgenic 
line, B03, which failed to express the transgene mRNA, 
had no cerebellar pathology. All of the remaining PS-82 
transgenic lines, however, had evidence of cerebellar ab- 
normalities. 
The transgenic lines with the earliest onset of ataxia 
tended to have the most severe neuropathologic changes. 
Transgenic lines B04 and B05 and lines B01 and B02 bred 
to homozygosity (Table 1) had evidence of significant loss 
of the Purkinje cell population, with Bergmann glial prolif- 
eration, and shrinkage and gliosis of the molecular layer 
(Figure 7). In addition, there were numerous ectopic Pur- 
two SCA1 patients with expanded alleles containing 82 and 55 CAG 
repeats reveals proteins of increased Mr. Analysis of protein expres- 
sion in isolated cerebella of transgenic animals with the PS-30 cDNA 
confirmed that the transgene is predominantly and abundantly ex- 
pressed in the cerebellum (data not shown). 
(B) Immunoblot analysis using an extended SDS-polyacrylamide g l 
demonstrates the presence of both wild-type murine ataxin-1 and a 
larger protein transgenic mice with the PS-30 transgene. A cross- 
reacting band of approximately 120 kDa is seen in brain samples in
both panels. This band has the same intensity n all lanes, indicating 
the equal loading of samples. 
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Figure 6. Ataxic Phenotype of a PS-82 Transgenic Animal 
A 30-week-old transgenic animal from line B05 displays clear signs 
of ataxia by falling to one side when walking. 
kinje cells present in the molecular layer and occasionally 
in the granular layer. Using immunostaining for calbindin, 
the dendritic arrays of the PS-82 transgenic mice also ap- 
peared to be abnormal (Figure 8). Occasional Purkinje 
cells had large clear vacuoles within their cytoplasm. Axo- 
nal torpedo bodies could not be identified. The granular 
layer in these mice was unremarkable. 
Heterozygous animals from transgenic lines B01 and 
B02 (Table 1), although not ataxic, had evidence of mild 
cerebellar pathology. There were occasional ectopic Pur- 
kinje cells in both the molecular and granular layers, but 
little or no suggestion of loss of Purkinje cells or gliosis. 
Transgenic line B06, while only mildly ataxic at the time 
examined (26 weeks), had somewhat more severe patho- 
logic changes, most of which were localized to Iobule IX in 
the posterior cerebellar cortex. In that Iobule, the changes 
resembled those described for the other ataxic transgenic 
lines. The remaining Iobules had only occasional ectopic 
Purkinje cells without evidence of significant neuronal 
loss. 
Discussion 
Targeted expression in transgenic mice of a SCA1 cDNA 
transgene carrying an expanded perfect CAG repeat with 
82 reiterations induced the loss of Purkinje cells from the 
cerebellar cortex and the neurological phenotype of ataxia. 
In contrast, transgenic mice generated using a SCA1 
cDNA carrying an unexpanded normal CAG repeat with 
30 reiterations had no cerebellar pathology or ataxia for 
more than 1 year, well past the age of onset of ataxia and 
neurodegeneration i  transgenic mice with an 82 repeat- 
containing transgene. These data demonstrate that, even 
though disorders associated with the expansion of tri- 
nucleotide repeats have yet to be observed in any species 
other than human, neurons within the mouse central ner- 
vous system (CNS) are susceptible to degeneration upon 
the expression of a SCA1 allele containing an expanded 
CAG repeat tract. 
A previous study reported that transgenic mice carrying 
a human AR cDNA with an expanded number of CAG 
repeats (45) failed to develop motor neuron disease similar 
to that observed in SBMA. This study by Bingham and 
colleagues (1995) demonstrated that although the AR 
transgene was transcribed, it was expressed at a level 
significantly lower than the wild-type endogenous AR 
gene. Bingham and coworkers suggested that the lack of 
an appropriate level of expression might account for the 
absence of a phenotypic effect. In the present study, we 
found levels of SCA1 transgene mRNA at least 10-fold 
greater than the endogenous level of Scal. Therefore, 
our results are consistent with the notion that expression 
levels may contribute to the induction of CAG repeat- 
based neurodegeneration in the mouse. It should, how- 
ever, be noted that the AR transgenic study used an ex- 
panded allele with only 45 CAG repeats. While this number 
of repeats is clearly within the size range for development 
of SBMA in humans, it is possible that mouse neurons 
have a reduced sensitivity to the detrimental effects of 
CAG repeat expansions. If so, our use of a SCA1 allele 
with 82 CAG repeats, almost twice the number of repeats 
used in the AR transgenic study, may have been another 
essential factor in the Purkinje cell neurodegeneration of 
the PS-82 transgenic mice. 
In two of the transgenic lines carrying an expanded 
SCA1 cDNA, B01 and B02, animals heterozygous for the 
transgene failed to develop a neurological phenotype, 
while animals homozygous for the transgene from these 
lines developed ataxia by 24 and 20 weeks, respectively. 
Histological examination of the cerebellum of a heterozy- 
gous transgenic animal from line B02 at 36 weeks of age 
did reveal cerebellar pathology. This result demonstrates 
that considerable neuropathology can occur without the 
manifestation of a neurological phenotype and is consis- 
tent with previous work demonstrating that overt ataxia 
occurs in mice only after there is loss or dysfunction of a 
substantial number (50%-75%) of the Purkinje cells (Fed- 
dersen et al., 1992, 1995). Thus, we conclude that the 
absence of an abnormal neurological phenotype in hetero- 
zygous animals from lines B01 and B02 reflects that Pur- 
kinje cell dysfunction progresses in these transgenic mice 
at a rate insufficient o cause ataxia over the time course 
of this study. By breeding the transgene to homozygosity, 
and thereby increasing the level of its expression, the pro- 
gression of Purkinje cell dysfunction was increased, and 
the development of ataxia occurred within the time frame 
of this study. 
In humans, while CAG repeats in the unexpanded range 
are stable, expanded SCA1 CAG repeats are subject to 
intergenerational instability, with a paternal bias for expan- 
sions (Chung et al., 1993; Jodice et al., 1994). Unlike the 
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Figure 7. Cerebellar Histology of Normal and 
Transgenic Mice Using Hematoxylin and Eosin 
Staining 
(A) Nontransgenic littermate control at 29 
weeks of age. 
(B) A06.2 transgenic mouse at 20 weeks with 
a normal cerebellar cortex structure• 
(C) B03 transgenic mouse at 24 weeks with a 
normal cerebellar cortex structure. 
(D) B01 homozygous transgenic mouse at 26 
weeks with an ectopic positioned Purkinje cell 
(indicated by the arrow), gliosis in the molecu- 
lar layer, and loss of Purkinje cells and gliosis 
in the Purkinje cell layer• 
(E) B02 homozygous transgenic mouse at 26 
weeks with ectopic positioned Purkinje cells, 
mild gliosis in molecular layer, and some disor- 
ganization of the Purkinje cell layer with mild 
Purkinje cell loss. 
(F) B04 transgenic mouse at 29 weeks with ec- 
topic positioned Purkinje cells, gliosis in the 
molecular layer, and loss of Purkinje cells and 
gliosis in the Purkinje cell layer. 
(G) B05 transgenic mouse at 16 weeks with 
Purkinje cell loss and gliosis. 
(H) B06 transgenic mouse at 26 weeks with an 
ectopic positioned Purkinje cell, but little evi- 
dence of Purkinje cell loss or gliosis. Pathology 
in B06 was mild and patchy in its distribution• 
Magnification, 168 x .  PCL denotes Purkinje 
cell layer. 
PCL- 
A Figure 8. Immunohistochemical Staining for 
Calbindin to Illustrate Purkinje Cell Morphology 
(A) Nontransgenic animal at 17 weeks of age 
displaying normal appearance of the cerebellar 
cortex. 
(B) B04 transgenic mouse at 17 weeks of age 
with ectopic Purkinje cells and disorganization 
of the Purkinje cell layer• 
(C) B05 transgenic mouse at 16 weeks of age 
with changes similar to those described in (B). 
(D) B06 transgenic mouse at 26 weeks of age 
with ectopic Purkinje cells and some Purkinje 
cell loss seen focally in Iobule IX. 
(Magnification, 165 x ) 
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observed instability of expanded SCA 1 alleles in humans, 
the SCA1 cDNA containing an expanded number of CAG 
trinucleotide repeats showed no variation in repeat length 
upon parent to offspring transmission in transgenic mice. 
Transgenic mice carrying an expanded CAG repeat in an 
AR cDNA transgene also exhibited intergenerational re- 
peat stability (Bingham et al., 1995). Thus, expanded CAG 
repeats positioned within cDNA transgenes fail to manifest 
intergenerational instability. The observed stability may 
reflect basic differences between mice and humans in 
their mechanisms of DNA repair, replication, or both. It 
also suggests that the chromosomal milieu of the CAG 
repeat may be an important factor in determining repeat 
instability. Sequences flanking the repeat or the repeat- 
containing gene, or the structure of the chromatin, may 
have a critical role in determining whether an expanded 
repeat is unstable upon transmission from parent to off- 
spring. The fact that a SCA1 allele of 82 repeats, which in 
humans had expanded from a paternal allele of 53 repeats 
and resulted in a juvenile form of disease, is stable in the 
mouse suggests that repeat number alone in the DNA 
and parental transmission effects is not sufficient o impart 
repeat instability. 
Recently, it has been demonstrated that the repeat units 
from the SCA1 gene, as well as other disease-associated 
genes with unstable trinucleotide repeats, are capable of 
forming a DNA hairpin structure in solution (Gacy et al., 
1995). The stability of the hairpin was found to be influ- 
enced not only by the length of the repeat, but also by the 
nucleotide sequence of the repeat and its flanking se- 
quences. These investigators uggested that hairpin sta- 
bility provides a structural basis for repeat instability. Gacy 
et al. (1995) found that a SCA1 of 25 repeats plus short 
stretches of flanking DNA formed a stable hairpin structure 
in solution. Although both transgene constructs used in 
this study contained CAG repeats greater than 25 repeats 
in length, as well as flanking sequences implicated in hair- 
pin formation, neither transgene including the SCA 1 trans- 
gene with 82 repeat units was found to be unstable in 
even a single parent to offspring transmission. If, in fact, 
a hairpin structure is formed within the SCA1 transgenes, 
the lack of intergenerational variability indicates that for- 
mation of this structure alone is not sufficient to induce 
repeat instability. Regardless of the mechanisms im- 
portant for repeat instability, the ability to induce neurode- 
generation in the SCA1 transgenic mice clearly demon- 
strates that pathogenesis can occur in the absence of 
repeat instability. 
In terms of SCA1 pathogenesis, the PS-82 transgenic 
mice are a model of the cerebellar component of the hu- 
man disease. Each of the transgenic lines expressing the 
PS-82 transgene was found to have substantial loss of 
Purkinje cells within the cerebellar cortex (Table 1 ; Figure 
7), a prominent pathological finding in human SCA1 nec- 
ropsy material (Zoghbi and Ballabio, 1995). Thus, the 
SCA1 transgenic mice recapitulate this important patho- 
logical feature of the human disease. Since regions of the 
brainstem that send projections to Purkinje cells are also 
involved in SCA1 pathology, it is conceivable that loss of 
Purkinje cells is due to a secondary effect. By directing the 
expression of the PS-82 transgene selectively to Purkinje 
cells, the present study demonstrates that the expression 
of an expanded SCA1 allele specifically induces the de- 
generation of these neurons, indicating that loss of Pur- 
kinje cells in SCA1, and hence development of ataxia, is 
due to a direct action of an expanded SCA1 allele on Pur- 
kinje neurons in a cell-autonomous fashion. 
Degeneration in SCA1 is not limited to Purkinje cells of 
the cerebellar cortex, but also includes neurons of the 
olives and certain lower motor neuron nuclei of the brain- 
stem (Zoghbi and Ballabio, 1995). In fact, it is the neuronal 
cell loss within the brainstem that is ultimately responsible 
for the lethal nature of SCA1. The use of other regulatory 
regions capable of directing transgene expression to 
broader neuronal cell types within the CNS should provide 
a means to determine whether expression of an expanded 
allele of SCA1 is also able to induce degeneration of other 
neuronal cell types in addition to cerebellar Purkinje cells. 
The presence of ectopically localized Purkinje cells was 
also a prominent feature of the cerebellar pathology of 
the PS-82 transgenic mice in this study. In an effort to 
investigate the possibility of similar pathologic anomalies 
in human SCA1, we have undertaken an initial pathologi- 
cal examination of cerebellar necropsy material from a 
juvenile case of human SCA1 resulting from a SCA 1 allele 
with 83 CAG repeats. The cerebellar findings include se- 
vere degeneration of Purkinje cells with Bergmann gliosis 
and shrinkage and gliosis of the molecular layer, similar 
to what was observed in the transgenic mice. Torpedo 
bodies, large dilatations of the proximal axons of Purkinje 
cells, a common feature of Purkinje cell degeneration in 
human ataxias (Koeppen and Barron, 1984), were abun- 
dant in the human case, but apparently absent in the ataxic 
mice. Although a small number of Purkinje cells were seen 
ectopically within the molecular layer, this finding was sub- 
stantially less striking than that observed in the affected 
transgenic mouse lines. It should be noted that the Pcp2 
regulatory region can direct transgene expression to em- 
bryonic stages, beginning at embryonic day 14 (Smeyne 
et al., 1991 ; Feddersen et al., 1995), which is substantially 
earlier than the transient burst of endogenous Scal ex- 
pression detectable around postnatal day 14 (S. Banff and 
H. Y. Z., unpublished ata). Furthermore, murine cerebel- 
lar development proceeds rapidly over a few weeks, as 
compared to many months in humans. These two factors 
might contribute to greater frequency of ectopic Purkinje 
cells in PS-82 transgenic mice that are not associated with 
SCA1 in humans. 
The mechanism by which CAG repeat expansions 
cause neurodegeneration in humans is not understood. 
The lack of neuropathology in males with a deletion of 
the AR (Quigley et al., 1992) and the absence of HD-like 
pathology in individuals with a heterozygous deletion of 
the HD gene (Gandelman et al., 1992; HDCRG, 1993) 
argue that the pathology caused by CAG repeat expansion 
is not simply the result of a loss-of-function mutation. How- 
ever, certain symptoms associated with SBMA, including 
gynecomastia and reduced fertility (Arbizu et al., 1983), 
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have been used to suggest that the wild-type function of 
the AR gene is partially compromised by the CAG repeat 
expansion (La Spada et al., 1991). The recent description 
of behavioral alterations and neuropathological changes 
in subthalamic nuclei of mice heterozygous for a targeted 
disruption of the HD gene raises the possibility that some 
of the symptoms een in these diseases may be secondary 
to a partial loss of function (Nasir et al., 1995). The pres- 
ence of a clinical phenotype intransgenic animals carrying 
a SCA1 cDNA with an expanded number of CAG repeats 
clearly demonstrates that mouse neurons are susceptible 
to mechanisms by which CAG repeat expansions cause 
neurodegeneration. Furthermore, data from the PS-82 
transgenic mice indicate that development of a phenotype 
is dependent upon transgene expression. Only those lines 
expressing the expanded PS-82 transgene developed a 
phenotype. Although line B03 contained 50 copies of the 
PS-82 transgene, it failed to express the transgene and did 
not develop ataxia or show signs of cerebellar pathology. 
These data argue that a gain of novel properties by the 
product of an expanded SCA1 allele is directly involved 
in the pathogenesis of this disorder. Moreover, if patho- 
genesis requires the interaction of mutant ataxin-1 with 
another cellular protein, the fact that expression of an ex- 
panded allele of SCA1 induces neurodegeneration in 
transgenic mice indicates that mice can be used as a 
source for proteins that specifically interact with mutant 
ataxin-1. Whether the symptoms associated with SCA1 
are also due to a partial loss of function will be determined 
by the analysis of mice with targeted disruptions of the 
SCA1 gene. 
Despite the substantial evels of transgene RNA de- 
tected in the cerebella of animals carrying either the PS-30 
or PS-82 constructs, human ataxin-1 derived from the 
transgene was detectable only in extracts of cerebella 
from mice expressing the PS-30 transgene. Animals dis- 
playing PS-82 message levels more than two orders of 
magnitude greater than murine Scal failed to produce 
levels of human ataxin-1 detectable by Western blot analy- 
sis. These results raise the possibility that the abnormal 
neurological phenotype may be dependent upon the pres- 
ence of RNA with an increased stretch of CAGs, rather 
than the presence of ataxin-1 with an expanded polyglu- 
tamine tract. There are, however, several observations 
contradictory to an RNA-based mechanism of neuronal 
degeneration. First, COS7 cell transfection studies using 
the SCA 1 cDNA with 82 trinucleotide repeats resulted in 
detectable levels of ataxin-1 with an expanded polygluta- 
mine tract, demonstrating that the employed cDNA en- 
codes a translatable mRNA. In addition, cerebella from 
transgenic animals carrying the PS-30 transgene express 
SCA1 RNA at levels 50- to 100-fold in excess of endoge- 
nous Scal. Thus, elevated levels of SCA1 mRNA are not, 
in themselves, pathogenic. Furthermore, protein extracts 
prepared from PS-30 transgenic erebella contain abun- 
dant amounts of human ataxin-1. Therefore, wild-type hu- 
man ataxin-1 can be expressed by murine Purkinje cells, 
and its expression is not detrimental to Purkinje cell differ- 
entiation, morphology, or function. In addition, the levels 
of PS-82 RNA found in cerebella from transgenic lines of 
the B0 series did not directly correlate with the onset of 
ataxia in these animals. For example, transgenic line B06 
expressed among the highest levels of PS-82 mRNA and 
yet had a relatively slow progression of pathology, whereas 
the B04 line had both the lowest transgene copy number 
and level of transgene mRNA, but developed early and 
pronounced pathology, indicating that the neurodegener- 
ation is not simply a consequence of expanded SCA1 
mRNA. 
Finally, M. R. Hayden and colleagues (personal commu- 
nication) have established a series of transgenic mice car- 
rying an expanded allele of the HD gene (IT15). These 
mice expressed substantial evels of transgene mRNA, 
but failed to express protein from the transgene owing to 
inclusion of DNA sequence in the 5' untranslated region, 
which acts as a repressor and an in-frame stop codon 
within the IT15 construct. The IT15 transgenic mice do 
not develop an abnormal neurological phenotype or CNS 
morphological alterations out to 6 months of age. These 
results further support the notion that pathology due to 
the expression of an expanded CAG repeat gene is not 
dependent on RNA. 
Detection of SCA1 mRNA in PS-82 transgenic mice at 
different ages (4-19 weeks) and with variable degrees of 
Purkinje cell degeneration (Table 1) argues against the 
loss of Purkinje cells being the sole reason for lack of 
detectable levels of mutant ataxin-1. Rather, the results 
suggest that ataxin-1 with an expanded number of gluta- 
mines expressed in Purkinje cells is either rapidly de- 
graded or modified such that it is no longer recognized 
by the anti-ataxin-1 antibody. If one assumes the mouse 
is an accurate model of pathogenesis, it might be hypothe- 
sized that mutant ataxin-1 is degraded or modified in hu- 
man Purkinje cells as in mouse. This would not necessarily 
be in conflict with available human data (Servadio et al., 
1995), since the detected expression of mutant ataxin-1 
in human cerebellum might have been derived from non- 
Purkinje cells, and the immunohistochemical staining of 
Purkinje cells in patients may have represented ataxin-1 
produced from the normal allele. Immunohistochemical 
examination of human SCA1 brain tissue with an antibody 
specific for mutant ataxin-1 would address this question. 
It is notable that Purkinje cells, a primary site of SCA1 
pathology, are unique in that they are the only cell type that 
has both cytoplasmic and nuclear localization of ataxin-1 
(Servadio et al., 1995). Therefore, it could be hypothesized 
that ataxin-1 is translocated to the nucleus in disease- 
related cell types; that mutant ataxin-1 is degraded or mod- 
ified in disease-related but not in other cell types; and that 
the degradation or alteration of mutant ataxin-1 is directly 
related to its gain-of-function property. 
The clinical and neuropathologic findings in multiple 
transgenic mouse lines harboring 82 CAG repeats within 
the SCA1 cDNA clearly demonstrate that gain of the ex- 
panded CAG tract within the SCA1 gene leads to Purkinje 
cell degeneration. The targeted expression to Purkinje 
cells and the absence of detectable mutant ataxin-1 in 
these cells will provide insight into the mechanism of 
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pathogenes is .  Furthermore,  the inabil ity to detect  mutant  
ataxin-1 in these cells, despi te  the character ist ic  patho logy  
and known translatabi l i ty  of  the mutant  protein,  may ex- 
plain the speci f ic i ty of  neurodegenerat ion  in SCAI .  Finally, 
it is hopeful  that  a mouse  model  of  neurodegenerat ion  
induced by the express ion  of  an expanded CAG repeat  can 
prov ide an in v ivo means  for test ing promis ing therapeut ic  
strategies.  
Experimental Procedures 
Transgene Construction 
The Pcp2/SCA1 transgenes were generated by joining the Pcp2 5' 
sequences, the human SCA/-coding region, and the SV40 polyadenyl- 
ation signal. In brief, an 835 bp SalI-Pvul fragment of the Pcp2 genomic 
sequences containing exon 1, intron 1, and a portion of exon 2, and 
a 237 bp BamHI-Bcll fragment containing the SV40 polyadenylation 
signal (Lebowitz and Weissman, 1979) were subcloned into pGEM11 
as previously described (Feddersen et al., 1992). This plasmid, Pur- 
kinje Cell Expression Vector II (PCEVII), also contains a truncated 
polylinker with Spel and Notl sites between the Pcp2 and SV40 se- 
quences. PCEVII was digested with Notl, treated with T4 polymerase 
to generate blunt ends, and then digested with Spel in preparation 
for the SCA1 insert. The EcoRI insert of cDNA clone 31-5 (containing 
base pairs 835-3516, including the entire coding region of the human 
SCA1 gene with 30 CAG repeats, base pairs 916-3384; Banff et al., 
1994) was initially subcloned into the EcoRI site of pBluescript SK(-). 
The SCA1 insert of this plasmid was then released with Spel (5' site) 
and EcoRV (3' blunt site) and directionally ligated into SpeI-Notl 
(blunt)-prepared PCEVII. The resulting plasmid contained the PS-30 
transgene, flanked by Sail restriction sites. The PS-82 transgene was 
generated by amplifying the CAG repeat tract from SCA1 patient DNA 
with primers A (5'-ACCGCCAACCCCGTCACC) and B (5'-GCTCTTCT- 
CCATCTCACCGT), digesting the products with Sfil, and then substi- 
tuting the Sfil fragment within the PS-30 transgene with the PCR prod- 
uct containing the expanded CAG tract (Figure 1). The described 
restriction fragment junctions and CAG repeat tracts were sequenced 
to confirm proper ligation and maintenance of reading frame. The 
transgene inserts were isolated by Sail digestion, gel purified, ex- 
tracted with organic solvent, and extensively dialyzed prior to microin- 
jection. 
Transgenic animals were identified using a transgene-specific PCR 
assay or by Southern analysis (or both). Postweaning tail biopsy DNA 
was generated as previously described (Hanley and Merlie, 1991). We 
used 0.1-1.0 ~g of DNA in a 25 p.I PCR reaction. The 5'primer, 5EX2B 
(5'-AGGTTCACCGGACCAGGAAGG), located within Pcp2 exon 2 and 
an ataxin-l-specific primer, Sau3A-40 (5'-ATGGAGTGGTGGCCC- 
CTG), were used to amplify a 581 bp transgene-specific fragment. 
Cycle conditions were 94°C (1 min), 57°C (1 min), and 72°C (2 min). 
Homozygous animals were distinguished from heterozygous lit- 
termates by densitometric omparisons of Southern blot hybridization 
intensities. 
Expression of Ataxin-1 in COS7 Cells 
SCA1 cDNAs containing either 30 or 82 CAG repeats were cloned into 
the EcoRI-digested plasmid of pcDL-SR~296 (Takebe et al., 1988). 
DNA (2 ~g) from each construct was individually mixed with 90 p.I of 
Optimem (GIBCO BRL) and subsequently mixed with 90 pJ of Optimem 
and 10 I~1 of lipofectamine (GIBCO BRL). A control plasmid containing 
the ~,-galactosidase gene was used to assess transfection efficiency. 
The optimal ratio of DNNlipofectaminelOptimem was evaluated by 
determining the number of COS7 cells that turned blue when 
transfected with the pcDL-SR~296-1~-galactosidase plasmid. The DNA/ 
lipofectamine mixture was set for 45 min at room temperature and 
then added to 6 x 104 COS7 cells, which were grown overnight in 
3.5 cm tissue culture dishes at 37°C in 10% CO2 incubators. Lipotrans- 
fection was stopped 4 hr later with 1 ml of DMEM medium, and the 
samples were incubated at 37°C in 10% CO2. 
70 hr later, the cells were washed three times with phosphate- 
buffered saline, and three times with TEE buffer (50 mM Tris [pH 8], 
5 mM EDTA, 5 mM EGTA). Cells were scraped from the dishes with 
300 p.I of TEE buffer a total of three times. Cells were subsequently 
pelleted and resuspended in 20 ml of TEE buffer containing 50 mM 
D-IF and 0.3% SDS. The samples were sonicated and spun, and 4 
p_l of the supernatant was analyzed by 7% SDS-PAGE and immu- 
noblotting using anti-ataxin-1 antiserum (11750 V). 
CAG Repeat PCR Analysis 
PCR reactions were performed as previously described (Orr et al., 
1993). In brief, each 15 p.I reaction contained 1 p_M Rep2 (5'-CAACAT- 
GGGCAGTCTGAG) and [y-32P]ATP-end-labeled Repl (5'-AACTGG- 
AAATGTGGACGTAC) primers, 250 I~M dNTPs, 2% formamide, t.25 
mM MgCI2, and 0.75 U of AmpliTaq polymerase. Cycling conditions 
were as follows: 94°C for 4 rain, followed by 30 cycles of denaturing 
at 94°C for I min, annealing at 57°C for 1 rain, extension at 72°C for 
1 min, and final elongation at 72°C for 8 min. A 6 p_l aliquot of the 
PCR was mixed with 4 Id of formamide-containing loading dye. After 
denaturation, 4-6 pJ of the mixture was run on a 4% sequencing gel 
and visualized by autoradiography. 
RNA Isolation and Northern Blot Analysis 
RNA was isolated from individual cerebella by the acid guanidinium 
thiocyanate-phenol/chleroform method (Chomczynski and Sacchi, 
1987). RNA samples were glyoxylated, fractionated on 10 mM sodium 
phosphate-agarose (1%) gels, and blotted onto nylon filters (Micro 
Separations Incorporated). Sizes were determined by using RNA 
markers (GIBCO BRL). Blots were stripped with a boiling 10 mM Tris, 
1% SDS solution prior to reprobing. 
Immunoblot Analysis and Preparation of Tissue Extracts 
Freshly collected mouse brains or cerebella were homogenized in 50 
mM Tris-HCI (pH 8.0), 1o/0 (v/v) Triton X-100, 0.5% (v/v) NP-40, 10 
mM BME, 40/0 (v/v) glycerol, plus a cocktail of 10 protease inhibitors. 
Samples were spun at 17,500 x g, and the supernatants were used 
for analysis of protein expression. Extracts from lymphoblastoid cells 
were prepared as previously described (Servadio et al., 1995). Protein 
extracts (160 p.g) were separated in a 6% SDS-polyacrylamide gel 
and transferred to nitrocellulose (Schleicher & Schuell). For the large 
gel (Figure 5B), 200 I~g of protein extracts were used. Blots were 
preblocked in TBST/NGS (20 mM Tris-HCI [pH 8.0], 150 mM NaCI, 
0.1% (v/v) Tween 20, 11% (v/v) normal goat serum. Sera were diluted 
1:6000 in TBST/NGS. The immune complexes were detected using a 
horseradish peroxidase-conjugated secondary antibody (Sigma) and 
enhanced chemiluminescence (Amersham). Anti-ataxin-1 (11750 V) 
antibodies were preabsorbed on nitrocellulose saturated with protein 
extracts from Escherichia coli expressing Maltose Binding Protein to 
reduce the background. 
Histological Examination and Immunohistochemistry 
Brains of transgenic and nontransgenic littermate mice were immer- 
sion fixed in 10% phosphate-buffered formalin for a minimum of 3 days. 
Tissue was processed by paraffin infiltration in midsagittal orientation. 
Sections were cut on a rotary microtome at 6-8 I~m, and routine histc- 
logic examination was done after staining with hematoxylin and eosin. 
Paraffin sections (6-6 p,m) of the tissues described above were 
deparaffinized and rahydrated through xylol and graded alcohols. Sec- 
tions were processed in citrate buffer (pH 6.0) using a microwave 
oven seven times for 3 min. Endogenous peroxidase was quenched by 
treatment with 6% hydrogen peroxide in methanol for 10 min. Sections 
were washed three times in 0.1 M phosphate-buffered saline (pH 7.5) 
for 6 rain, followed by a 20 min incubation with 10% normal horse 
serum in 0.1 M phosphate buffer (pH 7.5). Immunohistochemical de- 
tection of calbindin was performed using mouse monoclonal antibod- 
ies to calbindin (Sigma). Detection of primary antibodies was per- 
formed using routine avidin-biotin-peroxidase t chniques (Vector 
Labs). The diaminobenzidine reaction was enhanced with ions to form 
a black precipitate (DAB-Ni). After the reaction, the slides were washed 
in distilled water, counterstained with eosin, dehydrated in graded 
alcohols and xylol, and mounted. 
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